Galligan Andrew H 4
4 · NEVRO CORP · Filed Jan 10, 2020
Insider Transaction Report
Form 4
NEVRO CORPNVRO
Galligan Andrew H
VP of Finance , CFO
Transactions
- Exercise/Conversion
Common Stock
2020-01-08$63.23/sh+17,718$1,120,309→ 71,208 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-01-08−17,718→ 0 totalExercise: $63.23Exp: 2025-11-30→ Common Stock (17,718 underlying) - Sale
Common Stock
2020-01-08$120.11/sh−17,718$2,128,086→ 53,490 total
Footnotes (4)
- [F1]Includes 16,773 restricted stock units.
- [F2]The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- [F3]The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.74, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- [F4]Fully vested.